Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genomic hallmarks of localized, non-indolent prostate cancer

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE84043 | GEO | 2017/01/10

SECONDARY ACCESSION(S): PRJNA327861

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genomic hallmarks of localized, non-indolent prostate cancer

Project description:Prostate tumours are highly variable in their response to therapies, but clinically available prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 whole-genome sequences and 277 additional whole-exome sequences from localized, non-indolent prostate tumours with similar clinical risk profiles, and carried out RNA and methylation analyses in a subset. These tumours had a paucity of clinically actionable single nucleotide variants, unlike those seen in metastatic disease. Rather, a significant proportion of tumours harboured recurrent non-coding aberrations, large-scale genomic rearrangements, and alterations in which an inversion repressed transcription within its boundaries. Local hypermutation events were frequent, and correlated with specific genomic profiles. Numerous molecular aberrations were prognostic for disease recurrence, including several DNA methylation events, and a signature comprised of these aberrations outperformed well-described prognostic biomarkers. We suggest that intensified treatment of genomically aggressive localized prostate cancer may improve cure rates.

2017-01-10 | GSE83917 | GEO

Genomic hallmarks of localized, non-indolent prostate cancer

2017-01-10 | GSE84042 | GEO

Genomic hallmarks of localized, non-indolent prostate cancer

Project description:Genomic hallmarks of localized, non-indolent prostate cancer

| PRJNA327861 | ENA

Widespread and Functional RNA Circularization in Localized Prostate Cancer.

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-02-07 | GSE113124 | GEO

Paxillin regulates genomic networks in prostate cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-08-01 | GSE131731 | GEO

Integrative genomic profiling of human prostate cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2010-06-24 | GSE21032 | GEO

Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-04-01 | E-GEOD-77771 | biostudies-arrayexpress

Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-04-03 | E-GEOD-56470 | biostudies-arrayexpress

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Project description:While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Through integrative deep whole-genome and -transcriptome analysis of 101 castration-resistant prostate cancer metastases (109X tumor/38X normal coverage), we identified structural variants altering critical regulators of tumorigenesis and progression not detectable by exome approaches. Notably, we observed amplification of an intergenic enhancer region 624 kb upstream of the androgen receptor (AR) in 81% of patients, correlating with increased AR expression. Tandem duplication hotspots also occur near MYC, in lncRNAs associated with post-translational MYC regulation. Classes of structural variations were linked to distinct DNA repair deficiencies, suggesting their etiology, including associations of CDK12 mutation with tandem duplications, TP53 inactivation with inverted rearrangements and chromothripsis, and BRCA2 inactivation with deletions. Together, these observations provide a comprehensive view of how structural variations affect critical regulators in metastatic prostate cancer.

| S-EPMC6425931 | biostudies-literature

HPCX1 linked prostate cancer

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2011-12-31 | E-GEOD-24205 | biostudies-arrayexpress